Tantigen is an early-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to solving the bottlenecks that limit the use of cell therapy in low mutational burden solid tumors enabling personalized, platform agnostic cell therapy for all.
Tantigen is focused on the discovery of targets in pediatric cancers that are expressed across a range of adult indications, allowing development of treatments for neglected, rare indications as well as more common solid tumors.
Company Details
- Employees
- 2
- Founded
- 2021
- Address
- Philadelphia, Pa 19104, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.tantigenbio.com
- Keywords
- San Diego.
- HQ
- Philadelphia, PA
Tantigen Bio Questions
Tantigen Bio's website is https://www.tantigenbio.com
Tantigen Bio's LinkedIn profile is https://www.linkedin.com/company/tantigen-bio
Tantigen Bio has
2 employees.
View email and phone details for 2
employees at Tantigen Bio.
Tantigen Bio's industry is
Biotechnology Research
Tantigen Bio's top competitors are
Histologic Innovations,
Spirovant Sciences, Inc.,
Medspa Network,
Altus Growth Partners,
Thirdlaw Molecular,
Hula Therapeutics,
Candel Therapeutics,
Life Sciences Workforce Collaborative,
Nabriva Therapeutics Plc,
Eliksa Therapeutics.
Tantigen Bio's categories are Biotechnology Research
Tantigen Bio's founding year is 2021
